NCI Funds 4-Year Projects at 12 Tobacco Research Centers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 12
Volume 9
Issue 12

BETHESDA, Md-The National Cancer Institute (NCI) has launched its new antismoking initiative, Research in State and Community Tobacco Control Interventions, by awarding 12 grants totaling $13 million. The money will support the first year of 4-year research projects on local, state, and multistate tobacco prevention and control programs.

BETHESDA, Md—The National Cancer Institute (NCI) has launched its new antismoking initiative, Research in State and Community Tobacco Control Interventions, by awarding 12 grants totaling $13 million. The money will support the first year of 4-year research projects on local, state, and multistate tobacco prevention and control programs.

The first awards in the NCI program went to researchers at the University of Alabama at Birmingham; AMC Cancer Research Center, Denver; University of Illinois at Chicago; Battelle Centers for Public Health Research and Evaluation, Baltimore; and University of Massachusetts campuses at Amherst and Boston.

Grants also went to the University of Massachusetts Medical School; University of Minnesota School of Public Health; Roswell Park Cancer Institute; Oregon Research Institute, Eugene; Kaiser Permanente Center for Health Research, Portland, Oregon; and University of Texas Health Science Center at Houston.

Recent Videos
2 experts are featured in this series.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Related Content